PARP1 and cancer: PARP-based monotherapy is unlikely to encourage cancer cell death in BRCA-proficient tumors—the optimal chemotherapeutic option for the future remains the combination of PARP inhibition with either cytotoxic drugs or impairment of mechanisms of DNA repair.